News
The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...
16h
Investor's Business Daily on MSNApogee Dives. But It Could Eventually Rival Sanofi's Biggest Moneymaker.Apogee Therapeutics shares crumbled Monday despite promising results for what could become a quarterly or twice-yearly shot ...
Apogee is pitching APG777 as a 'best-in-class' IL-13 inhibitor that could offer robust efficacy and less-frequent dosing than ...
Ben Sutter could only eat three things after being diagnosed with eosinophilic gastroenteritis as a baby. A medical ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 20, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced that its Dupixent has been ...
Learn how Dupixent helps diverse eczema patients and why inclusive clinical trials are vital for fair healthcare.
13d
GlobalData on MSNFDA approves Sanofi and Regeneron’s Dupixent for bullous pemphigoidThe US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for ...
Despite Nektar’s share price shooting up as much as 175% on Tuesday, William Blair maintained that “there is an absence of ...
DUPIXENT can cause allergic reactions, including skin reactions, that can sometimes be severe. Stop using DUPIXENT and tell your healthcare provider or get emergency help right away if you get ...
The pharmaceutical industry spends a ton of money on drug ads. This should come as no surprise to anyone who watches TV or ...
Dupixent is a prescription drug that can be used to treat chronic rhinosinusitis due to nasal polyps. Learn more about side effects, dosage, and how it works for this condition.
EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results